Le Lézard
Classified in: Health
Subject: TRI

Gencove announces Phase I SBIR grant to validate polygenic risk score estimation from low-pass sequencing


NEW YORK, April 25, 2019 /PRNewswire/ -- Gencove, the leading low-pass sequencing platform announced today the receipt of a Phase I grant from the National Human Genome Research Institute under the auspices of the Small Business Innovation Research (SBIR) program of the National Institutes of Health. The grant will be used to validate methods for accurate calculation of polygenic risk scores from low-pass sequencing data that allow for population-scale screening applications, with a first application to coronary artery disease.

As clinical evidence for the benefit of screening patients for polygenic risk of diseases continues to accumulate, there will be increasing need for a scalable and flexible assay to measure these scores. Gencove's low-pass genome sequencing combined with its imputation algorithms can address the technological challenge to provide a highly accurate estimate of a polygenic risk score across ethnic groups using an assay that can scale financially and operationally to entire health care systems. Low-pass sequencing is an approach to combine the throughput and cost-effectiveness of genotyping arrays with the accuracy and population portability of whole genome sequencing.

Regarding this award, Gencove's CEO Joe Pickrell said, "The flexibility, operational efficiency, cost-effectiveness, and population-agnostic nature of low-pass sequencing make it a great choice for calculating polygenic risk scores at scale."

Gencove has recently raised a $3.2 million investment led by Spero Ventures.

About Gencove

Gencove is a spin-out of the New York Genome Center dedicated to making genomic data more accessible and interpretable through the development of molecular and computational tools. Gencove's flagship product is its low-pass genome sequencing platform; the company operates a laboratory in New York and offers both low-pass sequencing and analytics software as a service, with customers that include top academic institutions, biotechnology and pharmaceutical companies. More information is available at www.gencove.com.

Contact: Maria Vazquez, maria.vazquez@gencove.com

SOURCE Gencove


These press releases may also interest you

at 17:54
Summary Product: Certain hand sanitizers made with industrial-grade ethanol Issue: Health Canada is advising Canadians that certain hand sanitizers are being recalled from the market because they contain industrial-grade ethanol that has not been...

at 17:18
How should universities evolve and innovate as the world enters a new phase with the fourth industrial revolution, accelerated by the COVID-19 pandemic? World's Universities with Real Impact (WURI) invites educators, researchers, data scientists, and...

at 17:00
One of the largest and most prestigious dental clinics in Mexico, Sani Dental Group, is the first and only dental group in the region with the COVID-19 Trust Shield Certificate from Dental Departures. The COVID-19 Trust Shield Certificate truly...

at 13:45
Ten schools in Los Angeles County will receive free masks, gloves, and sanitizer from Health Supply World, a local startup company with a mission to reduce the unmet need for personal protective equipment (PPE). Health Supply World invites L.A....

at 12:49
The COVID-19 pandemic has emphasized the day-to-day obstacles that persons with disabilities face and the Government of Canada remains dedicated to working with partners across the country to build a more accessible and inclusive Canada. Today, as...

at 12:38
In lieu of a daily in-person update to the media, Dr. Theresa Tam, Canada's Chief Public Health Officer, issued the following statement today: "As of end of day Friday, June 5, there are now 94,335 confirmed cases including 7,703 deaths and 52,568 or...



News published on 25 april 2019 at 21:17 and distributed by: